Education
About Us
Working with TipRanks
Follow Us
Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
IMMX Stock Chart & Stats
$4.32
-$0.03(-1.32%)
At close: 4:00 PM EST
$4.32
-$0.03(-1.32%)
Day’s Range― - ―
52-Week Range$1.34 - $7.73
Previous Close$2.25
Volume74.23K
Average Volume (3M)683.60K
Market Cap
$266.11M
Enterprise ValueN/A
Total Cash (Recent Filing)$15.95M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding52,695,520
10 Day Avg. Volume476,730
30 Day Avg. Volume683,602
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)4.70
Price to Sales (P/S)0.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$8.00Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyNXC-201 achieved a 75% hematologic complete response rate in the NEXICART-2 trial for relapsed/refractory AL amyloidosis, indicating strong potential efficacy for a condition with few treatment alternatives.
Regulatory Outlook And FinancingAnalysts increased the probability of approval for NXC-201 to 85% and a recent $100 million equity raise supported a Buy rating and an upward revision of the 12-month price target, reflecting stronger funding and perceived regulatory prospects.
Safety ProfileNEXICART-2 safety data showed no Grade 3-or-higher cytokine release syndrome and no neurotoxicity events, supporting a favorable tolerability profile versus many other cell therapies.
Bears Say
Competitive RiskEmerging therapy Etentamig presents a competitive threat in the relapsed/refractory AL amyloidosis market, which could constrain NXC-201's eventual market share and pricing power if Etentamig gains clinical traction.
Immix Biopharma News
IMMX FAQ
What was Immix Biopharma, Inc.’s price range in the past 12 months?
Immix Biopharma, Inc. lowest stock price was $1.34 and its highest was $7.73 in the past 12 months.
What is Immix Biopharma, Inc.’s market cap?
Immix Biopharma, Inc.’s market cap is $266.11M.
When is Immix Biopharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immix Biopharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Immix Biopharma, Inc. overvalued?
According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued.
Does Immix Biopharma, Inc. pay dividends?
Immix Biopharma, Inc. does not currently pay dividends.
What is Immix Biopharma, Inc.’s EPS estimate?
Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has 52,695,520 shares outstanding.
What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immix Biopharma, Inc.?
Currently, no hedge funds are holding shares in IMMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immix Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (85.19% Upside)
$8.00 (85.19% Upside)
Blogger Sentiment
Bullish
IMMX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.63%
12-Months-Change
Fundamentals
Return on Equity
-182.55%
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
IMMX Stock 12 Month Forecast
Average Price Target
$8.00
▲(85.19% Upside)
Technical Analysis
Alterity Therapeutics
―
VistaGen Therapeutics
―
―
MindWalk Holdings
―
MiNK Therapeutics
―
Ownership Overview
23.17% Insiders
1.52% Mutual Funds
2.08% Other Institutional Investors
71.86% Public Companies and
Individual Investors